Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type-2 diabetes management, have emerged as powerful tools in obesity treatment [1,2]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.